COX-2 Inhibitors and Cardiovascular Risk

@article{Cannon2012COX2IA,
  title={COX-2 Inhibitors and Cardiovascular Risk},
  author={C. Cannon and P. Cannon},
  journal={Science},
  year={2012},
  volume={336},
  pages={1386 - 1387}
}
The vascular location of an enzyme accounts for the cardiovascular hazards associated with its inhibition. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used by millions of people worldwide to reduce pain and inflammation. They exert their pharmacologic effect by inhibiting the cyclooxygenase-1 (COX-1) and COX-2 enzymes, thereby blocking conversion of arachidonic acid to prostaglandin E2 (PGE2) and PGI2 (prostacyclin), which mediate pain (see the figure). However, because COX enzymes exist… Expand
The Coxib case: Are EP receptors really guilty?
TLDR
Coxibs changes may powerfully synergize with NSAID-induced prostaglandin (PG) modifications, thus regulating vascular side effects, and seem to determine NSAID safety also. Expand
NSAIDs and cardiovascular risk
TLDR
The aim of this document is to review side-effects profile of NSAIDs and, specifically, to investigate cardiovascular consequences ofNSAIDs use in clinical practice. Expand
The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
TLDR
VA694 is a promising COX2-inhibiting hybrid drug, showing NO releasing properties which may mitigate the CV deleterious effects associated with the COX 2-inhibition. Expand
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
TLDR
This review focuses on PGE2, and in particular on the role of the individual EP receptors and their signalling pathways in neoplastic disease, and the potential for exploiting the EP receptors as therapeutic targets for the treatment of cancer and metastatic disease. Expand
The endothelial cyclooxygenase pathway: Insights from mouse arteries.
TLDR
Evidence that supports a role for COX-1 as the major mediator of PGI2 synthesis in mouse vascular endothelium, reasons for the inconsistency, and results that elucidate underlying mechanisms for divergent vasomotor reactions to endothelial COX activation will be discussed in this review. Expand
Is the cardiovascular toxicity of NSAIDS and COX-2 selective inhibitors underestimated in patients with haemophilia?
TLDR
Compared with nonselective non-steroidal anti-inflammatory drugs (ns-NSAIDs), selective COX-2 inhibitors (coxibs) offer the major advantage of not increasing the bleeding risk, thus being a better choice of analgesics for haemophilia patients. Expand
Valdecoxib: the rise and fall of a COX-2 inhibitor
TLDR
The therapeutic potential and the adverse events of valdecoxib are examined utilising a pubmed and web of sciences search to select literature on this subject and the limitations of the research supporting the withdrawal are discussed. Expand
The role of prostaglandin E2 in human vascular inflammation.
TLDR
Understanding the roles of PGE2 and its cognate receptors in vascular diseases could help to identify diagnostic and prognostic biomarkers and from these recent studies new promising therapeutic approaches like mPGES-1 inhibition and/or EP4-antagonism should be investigated. Expand
The role of prostaglandin E 2 in human vascular in fl ammation
Prostaglandins (PG) are the product of a cascade of enzymes such as cyclooxygenases and PG synthases. Among PG, PGE2 is produced by 3 isoforms of PGE synthase (PGES) and through activation of itsExpand
Celecoxib for the treatment of musculoskeletal arthritis
TLDR
There is still much to learn, especially regarding the prescription of celecoxib in patients with cardiovascular co-morbidities, while low doses seem to be safe according to present data, the knowledge on the more effective, higher doses >400 mg/day is still limited. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Risk of cardiovascular events associated with selective COX-2 inhibitors.
TLDR
The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials. Expand
Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice
TLDR
Suppression of PGI2 formation due to deletion of vascular COX-2 is sufficient to explain the cardiovascular hazard from NSAIDs, which may be augmented by secondary mechanisms such as suppression of NO production. Expand
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.
TLDR
Questions that remain to be addressed are whether this hazard extends to all or some of the traditional NSAIDs; whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and how to identify individuals most likely to benefit or suffer from such drugs in the future. Expand
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
TLDR
The data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition ofcox-1. Expand
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Prostaglandins (PG) are synthesized by two isoforms of the enzyme PG G/H synthase [cyclooxygenase (COX)]. To examine selectivity of tolerated doses of an inhibitor of the inducible COX-2 in humans,Expand
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2
TLDR
It is shown that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI2receptor but are depressed in mice genetically deficiencies in the TxA2 receptor (TP) or treated with a TP antagonist. Expand
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
TLDR
There was a significant increase in the rate ratio for myocardial infarction with COX-2 inhibitors compared with placebo, and regulatory authorities in several regions of the world have introduced warning statements and advisories to both healthcare professionals and the lay public about the use of various NSAIDs. Expand
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population
TLDR
This study adds support to the hypothesis that chronic treatment with some t NSAIDs is associated with a small increased risk of non-fatal MI, and is consistent with a substantial variability in cardiovascular risks between individual tNSAIDs. Expand
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups. Expand
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
TLDR
Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs. Expand
...
1
2
...